Literature DB >> 11157008

Anthracycline adjuvant chemotherapy: how much is enough?

M Levine, A Eisen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157008     DOI: 10.1200/JCO.2001.19.3.599

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.

Authors:  Margot Burnell; Mark N Levine; Judith-Anne W Chapman; Vivien Bramwell; Karen Gelmon; Barbara Walley; Ted Vandenberg; Haji Chalchal; Kathy S Albain; Edith A Perez; Hope Rugo; Kathleen Pritchard; Patti O'Brien; Lois E Shepherd
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

2.  Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist.

Authors:  Kathinka E Pitman; Kine M Bakke; Alexandr Kristian; Eirik Malinen
Journal:  Cancer Imaging       Date:  2019-12-19       Impact factor: 3.909

3.  Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.

Authors:  Min Kyoung Kim; Jin Hee Ahn; Sung-Bae Kim; Young-Suk Im; Soon Im Lee; Sei-Hyun Ahn; Byung Ho Son; Gyungyub Gong; Hak-Hee Kim; Woo Kun Kim
Journal:  Korean J Intern Med       Date:  2007-12       Impact factor: 2.884

4.  Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.

Authors:  K Towns; P L Bedard; S Verma
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.